Cytokinetics 향후 성장
Future 기준 점검 2/6
Cytokinetics (는) 각각 연간 55.1% 및 51.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 56.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -2133.4% 로 예상됩니다.
핵심 정보
55.1%
이익 성장률
56.73%
EPS 성장률
| Biotechs 이익 성장 | 29.0% |
| 매출 성장률 | 51.9% |
| 향후 자기자본이익률 | -2,133.42% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 10 Sep 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • Aug 12
CYTK: Future Returns Will Depend On HCM Launch And Nonobstructive Phase 3 Data
The analyst fair value estimate for Cytokinetics has moved from $83 to $85, reflecting updated views on Myqorzo launch momentum, higher long term sales potential, and recent price target increases across several firms. Analyst Commentary Recent Street research on Cytokinetics reflects a generally constructive view on Myqorzo and the companys long term potential, with several firms updating models following Q1 and Q2 results.
내러티브 업데이트 • Jul 28
CYTK: Myqorzo Launch Adoption And ACACIA HCM Expansion Will Drive Upside
The fair value estimate for Cytokinetics has been revised slightly higher to $107.80, as analysts factor in updated price targets, generally positive views on the Myqorzo launch, physician adoption trends, and potential long-term contributions from non obstructive HCM indications. Analyst Commentary Recent Street research on Cytokinetics points to generally constructive views on the Myqorzo launch and the broader pipeline, with several firms adjusting price targets and ratings as they update models and earnings previews.Seeking Alpha • Jul 22
Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise
Summary Cytokinetics (CYTK) is positioned to expand MYQORZO across the entire HCM continuum, not just as a late-stage competitor to Camzyos. Initial MYQORZO launch metrics—rapid market access, >30% new-to-brand share, and strong prescriber uptake—signal robust commercial traction beyond headline Q1 revenue. MAPLE-HCM and ACACIA-HCM trials support earlier use and a potential doubling of the addressable market via non-obstructive HCM, driving CYTK’s long-term value. CYTK’s $1.9B liquidity post-equity raise funds aggressive expansion, but high SG&A, regulatory, and IP risks remain critical to monitor as MYQORZO scales. Read the full article on Seeking Alpha내러티브 업데이트 • Jul 14
CYTK: Future Returns Will Rely On HCM Execution And Phase 3 Outcomes
The updated fair value estimate for Cytokinetics moves to $83.00 from $72.08 as analysts factor in higher modeled revenue growth, modestly stronger profit margins, and ongoing Street support tied to Myqorzo launch momentum, expanded HCM opportunities, and refreshed targets from firms across the biotech sector. Analyst Commentary Street research on Cytokinetics currently reflects a mix of enthusiasm around the Myqorzo launch and the hypertrophic cardiomyopathy pipeline, alongside a more measured tone on execution risks and valuation.내러티브 업데이트 • Jun 30
CYTK: Global Heart Drug Launch And ACACIA Data Will Drive Next Upswing
The fair value estimate for Cytokinetics has been updated from $92.94 to $105.60. This change reflects analysts' higher price targets driven by early Myqorzo launch momentum in obstructive hypertrophic cardiomyopathy, stronger peak sales assumptions, and added long-term potential from possible non-obstructive HCM expansion.분석 기사 • Jun 19
Cytokinetics (CYTK) Stock Could Be 15% Undervalued After Myqorzo Approval
Cytokinetics (CYTK) is back in focus after the FDA cleared its first commercial product, Myqorzo, for symptomatic obstructive hypertrophic cardiomyopathy, with early launch data and European approvals drawing fresh attention to the stock. See our latest analysis for Cytokinetics. Against this backdrop, Cytokinetics' short term share price momentum has been strong, with a 7 day share price return of 13.73% and a 90 day share price return of 27.68%. Its 1 year total shareholder return of...
내러티브 업데이트 • Jun 16
CYTK: HCM Launch And ACACIA Phase 3 Readout Will Drive Repricing
The analyst price target for Cytokinetics has been revised higher by $5 to $99, with analysts pointing to optimism around the Myqorzo launch in obstructive hypertrophic cardiomyopathy and underappreciated potential in nonobstructive disease, supported by expectations around fuller Phase 3 ACACIA-HCM data. Analyst Commentary Recent research on Cytokinetics highlights a cluster of bullish analysts who are focused on execution around the Myqorzo launch, the potential in nonobstructive hypertrophic cardiomyopathy, and upcoming clinical data from the ACACIA-HCM program.내러티브 업데이트 • Jun 02
CYTK: Positive HCM Data And Launch Execution Will Drive 2026 Repricing Potential
Analysts have nudged Cytokinetics' fair value estimate higher from about $123.09 to $136.89, citing increased confidence in the Myqorzo launch in obstructive hypertrophic cardiomyopathy, as well as potential upside from nonobstructive disease, as key drivers behind recent price target increases and new coverage initiations. Analyst Commentary Recent Street research around Cytokinetics centers on expectations for the Myqorzo launch in obstructive hypertrophic cardiomyopathy and the potential extension into nonobstructive disease.분석 기사 • May 17
Need To Know: Analysts Are Much More Bullish On Cytokinetics, Incorporated (NASDAQ:CYTK) Revenues
Shareholders in Cytokinetics, Incorporated ( NASDAQ:CYTK ) may be thrilled to learn that the analysts have just...내러티브 업데이트 • May 14
CYTK: Future Returns Will Depend On HCM Launch And ACACIA Readout
Analysts have raised their average price target for Cytokinetics by about $5, citing a mix of updated trial expectations, improved projected profit margins, and adjustments to long term valuation assumptions. Analyst Commentary Recent research updates highlight a generally constructive stance on Cytokinetics, with several large firms lifting their price targets following product approval milestones, early launch indicators for Myqorzo in obstructive hypertrophic cardiomyopathy, and upcoming Phase 3 readouts in non obstructive disease.분석 기사 • May 07
Earnings Update: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Are Boosting Their Estimates
The investors in Cytokinetics, Incorporated 's ( NASDAQ:CYTK ) will be rubbing their hands together with glee today...내러티브 업데이트 • Apr 29
CYTK: ACACIA Trial Readout Will Drive Next Phase Of Momentum
The analyst price target for Cytokinetics has shifted higher to $92.94 from $79.56, with analysts pointing to stronger modeled revenue growth, a higher future P/E assumption tied to growing interest in Myqorzo and ACACIA trial catalysts, as well as updated discount rate and margin forecasts. Analyst Commentary Recent research updates cluster around the same core themes, with most activity tied to reactions to Myqorzo approval for obstructive hypertrophic cardiomyopathy, expectations for the ACACIA non obstructive HCM trial, and tweaks to long term loss and margin forecasts.내러티브 업데이트 • Apr 14
CYTK: Future Returns Will Hinge On HCM Launch And ACACIA Trial Outcome
The analyst price target for Cytokinetics is now set at $67.00. This level is supported by analysts highlighting early Myqorzo launch traction in obstructive hypertrophic cardiomyopathy, growing focus on upcoming non obstructive HCM data, and updated assumptions around expenses and interest income.내러티브 업데이트 • Mar 31
CYTK: Future Returns Will Depend On HCM Launch And ACACIA Outcome
Cytokinetics' fair value estimate has been revised to $67 from $61, reflecting analysts' higher price targets tied to early Myqorzo launch signals and the potential impact of upcoming ACACIA non obstructive HCM data. Analyst Commentary Recent Street research on Cytokinetics has centered on two main themes: Myqorzo's early launch trends in obstructive hypertrophic cardiomyopathy and the upcoming ACACIA readout in non obstructive HCM.내러티브 업데이트 • Mar 17
CYTK: Upcoming ACACIA nHCM Readout Will Drive 2026 Repricing Potential
Analysts have raised their average price targets for Cytokinetics, citing updated views on the ACACIA nHCM trial, early MYQORZO launch progress, and revised loss and expense assumptions. Together, these factors support a slightly higher fair value estimate of about $123 per share.내러티브 업데이트 • Mar 03
CYTK: Future Returns Will Depend On HCM Data And Launch Execution
Analysts have lifted their average price targets on Cytokinetics by several dollars into a $67 to $101 range, citing Q4 updates, early MYQORZO launch traction in obstructive hypertrophic cardiomyopathy, and expectations around upcoming ACACIA trial data in both obstructive and non obstructive HCM. Analyst Commentary Across recent research updates, analysts have been adjusting their models and views on Cytokinetics around Q4 results, the early MYQORZO launch in obstructive hypertrophic cardiomyopathy, and expectations for the ACACIA program in both obstructive and non obstructive HCM.내러티브 업데이트 • Feb 17
CYTK: Fair Value Reset Will Hinge On Execution Of Commercial Transition
The analyst fair value estimate for Cytokinetics has moved to $61 from $55. This change reflects updated views from recent Street research that highlight revised revenue growth, profit margin, and P/E assumptions following a series of price target increases across several firms.내러티브 업데이트 • Feb 03
CYTK: 2026 HCM Launch And Cost Discipline Will Shape Repricing Potential
Analysts have nudged their fair value target for Cytokinetics higher from about US$120 to roughly US$122 per share, reflecting updated revenue, margin and P/E assumptions following a series of recent price target increases and Overweight or Outperform views across several firms. Analyst Commentary Recent Street research has largely leaned constructive on Cytokinetics, with several bullish analysts revisiting their models and price targets around key pipeline and financial milestones.분석 기사 • Jan 27
Need To Know: The Consensus Just Cut Its Cytokinetics, Incorporated (NASDAQ:CYTK) Estimates For 2026
Market forces rained on the parade of Cytokinetics, Incorporated ( NASDAQ:CYTK ) shareholders today, when the analysts...내러티브 업데이트 • Jan 19
CYTK: Anticipated 2026 HCM Launch Will Drive Repricing Potential
Narrative Update on Cytokinetics The analyst price target for Cytokinetics has been nudged higher in line with a modest fair value increase to about $120.25, as analysts factor in updated revenue and expense modeling around the potential 2026 launch of aficamten and continued interest in U.S. small to mid cap biotech names. Analyst Commentary Recent research updates around Cytokinetics center on recalibrated price targets and refreshed modeling for aficamten and operating expenses, as analysts refine their views ahead of a potential 2026 commercial launch.내러티브 업데이트 • Jan 05
CYTK: Aficamten Launch Path And Cash Outlook Will Drive Repricing
Analysts have lifted their price targets on Cytokinetics, with recent moves such as RBC's increase to US$87 and BofA's incremental raises to US$63. These changes reflect updated modeling on operating expenses, revenue assumptions around the anticipated 2026 aficamten launch, and revised net cash forecasts.내러티브 업데이트 • Dec 17
CYTK: Elevated Expectations For 2026 Launch Will Likely Prove Difficult To Sustain
The analyst price target for Cytokinetics has been raised from $41.00 to $55.00 as analysts factor in stronger aficamten launch expectations, higher long term revenue growth and margin assumptions, and updated operating expense forecasts informed by recent Street research. Analyst Commentary Recent Street research on Cytokinetics reflects a constructive but increasingly nuanced outlook as the aficamten launch approaches.내러티브 업데이트 • Dec 03
CYTK: Momentum Will Build Ahead Of Late Cycle FDA Decision
Analysts have nudged their blended price target for Cytokinetics modestly higher, with our fair value estimate increasing from about $78.44 to $79.56. Updated models reflect stronger long term aficamten launch dynamics, refined operating expense assumptions, and incremental confidence around regulatory and commercial execution.내러티브 업데이트 • Nov 19
CYTK: Momentum Will Build Ahead Of Anticipated FDA Decision Next Year
Analysts have modestly raised their price targets for Cytokinetics, with updated forecasts supported by expectations for robust aficamten launch dynamics, improved projected revenue growth, and refined operating expense assumptions. This has led to an increase in fair value from $76.67 to $78.44 per share.내러티브 업데이트 • Nov 05
CYTK: Strong Cardiology Data Will Drive Momentum Ahead Of December 2025 FDA Decision
Analysts have modestly raised their price target for Cytokinetics, increasing it by nearly $1 to approximately $76.67. They cite ongoing favorable feedback on aficamten from recent medical meetings and firm research updates.내러티브 업데이트 • Oct 22
Analyst Commentary Highlights Shifting Sentiment on Cytokinetics Amid Aficamten Progress and Valuation Changes
Analysts have raised their average price target for Cytokinetics by approximately $1.42 to $75.83. This reflects increased confidence in aficamten's upcoming launch and updated forecasts following positive regulatory and clinical developments.내러티브 업데이트 • Sep 18
Precision Medicine And Late-stage Trials Will Expand Global Reach
Cytokinetics’ consensus price target was modestly raised to $74.41, as strong MAPLE trial data for aficamten de-risked its profile, reinforced first-line oHCM potential, and highlighted underappreciated pipeline optionality, all outweighing near-term market adoption headwinds. Analyst Commentary Bullish analysts highlighted strong MAPLE trial data for aficamten presented at ESC, reinforcing confidence in its clinical value and de-risked, best-in-disease positioning for oHCM.내러티브 업데이트 • Sep 03
Precision Medicine And Late-stage Trials Will Expand Global Reach
Upward revisions in analyst price targets for Cytokinetics reflect increased confidence in aficamten’s strong Phase 3 data, anticipated favorable FDA outcomes, and expanded commercial prospects, partially offset by concerns over possible REMS limitations and launch pacing, resulting in a higher consensus price target of $73.21. Analyst Commentary Bullish analysts highlight strong Phase 3 MAPLE-HCM and extension study data for aficamten, citing de-risked profile and high efficacy/safety, increasing their confidence ahead of regulatory decisions.새로운 내러티브 • Aug 10
Precision Medicine And Late-stage Trials Will Expand Global Reach
Successful late-stage clinical trials, commercial readiness, and diversification in products position the company for strong growth and reduced dependence on a single therapy.이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 889 | -326 | -418 | -279 | 16 |
| 12/31/2027 | 425 | -649 | -616 | -536 | 20 |
| 12/31/2026 | 150 | -809 | -726 | -767 | 21 |
| 6/30/2026 | 68 | -894 | -581 | -555 | N/A |
| 3/31/2026 | 106 | -830 | -549 | -524 | N/A |
| 12/31/2025 | 88 | -785 | -535 | -510 | N/A |
| 9/30/2025 | 87 | -752 | -453 | -433 | N/A |
| 6/30/2025 | 86 | -606 | -439 | -427 | N/A |
| 3/31/2025 | 19 | -615 | -408 | -398 | N/A |
| 12/31/2024 | 18 | -590 | -400 | -396 | N/A |
| 9/30/2024 | 3 | -576 | -407 | -404 | N/A |
| 6/30/2024 | 3 | -545 | -401 | -399 | N/A |
| 3/31/2024 | 4 | -531 | -423 | -422 | N/A |
| 12/31/2023 | 8 | -526 | -416 | -414 | N/A |
| 9/30/2023 | 8 | -527 | -443 | -438 | N/A |
| 6/30/2023 | 10 | -540 | -437 | -426 | N/A |
| 3/31/2023 | 98 | -431 | -406 | -395 | N/A |
| 12/31/2022 | 95 | -389 | -311 | -300 | N/A |
| 9/30/2022 | 148 | -282 | -272 | -246 | N/A |
| 6/30/2022 | 151 | -216 | -236 | -201 | N/A |
| 3/31/2022 | 65 | -258 | -183 | -140 | N/A |
| 12/31/2021 | 70 | -215 | -191 | -143 | N/A |
| 9/30/2021 | 22 | -229 | -83 | -46 | N/A |
| 6/30/2021 | 58 | -156 | -17 | 8 | N/A |
| 3/31/2021 | 59 | -135 | -7 | 10 | N/A |
| 12/31/2020 | 56 | -127 | -2 | 9 | N/A |
| 9/30/2020 | 54 | -114 | -68 | -62 | N/A |
| 6/30/2020 | 19 | -140 | -101 | -97 | N/A |
| 3/31/2020 | 22 | -132 | N/A | -94 | N/A |
| 12/31/2019 | 27 | -122 | N/A | -91 | N/A |
| 9/30/2019 | 31 | -118 | N/A | -84 | N/A |
| 6/30/2019 | 36 | -110 | N/A | -96 | N/A |
| 3/31/2019 | 35 | -105 | N/A | -98 | N/A |
| 12/31/2018 | 32 | -106 | N/A | -101 | N/A |
| 9/30/2018 | 22 | -120 | N/A | -113 | N/A |
| 6/30/2018 | 18 | -131 | N/A | -106 | N/A |
| 3/31/2018 | 14 | -132 | N/A | -111 | N/A |
| 12/31/2017 | 13 | -128 | N/A | -102 | N/A |
| 9/30/2017 | 47 | -80 | N/A | 0 | N/A |
| 6/30/2017 | 99 | -14 | N/A | 14 | N/A |
| 3/31/2017 | 102 | 3 | N/A | 34 | N/A |
| 12/31/2016 | 106 | 16 | N/A | 37 | N/A |
| 9/30/2016 | 83 | 0 | N/A | -51 | N/A |
| 6/30/2016 | 32 | -42 | N/A | -49 | N/A |
| 3/31/2016 | 33 | -41 | N/A | -47 | N/A |
| 12/31/2015 | 29 | -38 | N/A | 5 | N/A |
| 9/30/2015 | 41 | -20 | N/A | 7 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: CYTK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: CYTK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: CYTK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: CYTK 의 수익(연간 51.9%)이 US 시장(연간 13.4%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: CYTK 의 수익(연간 51.9%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: CYTK는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/13 16:40 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Cytokinetics, Incorporated는 37명의 분석가가 다루고 있습니다. 이 중 21명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Emily Field | Barclays |
| Hang Hu | Barclays |
| Carter Gould | Barclays |